Argent Biopharma (AU:RGT) has released an update.
Argent Biopharma Limited has disclosed a significant off-market acquisition of fully paid ordinary shares by Director Roby Reuven Zomer, with the indirect interest of HSBC Custody Nominees (Australia) Limited increasing by 1,258,500 shares, valued at approximately A$503,400. This change in director’s interest has been reported to the ASX in compliance with listing rule 3.19A.2, reflecting a strengthened investment by Zomer in the company.
For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.
